Absci (ABSI) Net Equity Issued and Repurchased (2020 - 2026)
Absci (ABSI) reported Net Equity Issued and Repurchased of $8.0 million for Q1 2026, down 80.91% on a YoY basis from $41.7 million in Q1 2025, and up 127.41% sequentially from $3.5 million in Q4 2025.
Absci (ABSI) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 80.91% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $72.1 million (up 66.67% YoY), and the FY2025 full-year result was $105.8 million, up 28.44% from the prior year.
- Net Equity Issued and Repurchased improved to $8.0 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $80.8 million in Q1 2024 to a low of -$2.2 million in Q4 2024.
- A 5-year average of $12.3 million and a median of $304500.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
- Across the five-year window, Net Equity Issued and Repurchased slumped 1198.48% in 2023 and soared 35195.63% in 2024, its largest moves.
- Tracing ABSI's Net Equity Issued and Repurchased over 5 years: stood at $66000.0 in 2022, then tumbled by 1198.48% to -$725000.0 in 2023, then sank by 204.69% to -$2.2 million in 2024, then soared by 258.4% to $3.5 million in 2025, then surged by 127.41% to $8.0 million in 2026.
- Business Quant data shows ABSI's Net Equity Issued and Repurchased at $8.0 million in Q1 2026, $3.5 million in Q4 2025, and $60.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | 7.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.96 Mn |
| Mar 31, 2026 | 7.96 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 60.65 Mn |
| Sep 30, 2025 | 60.65 Mn |
| Mar 31, 2025 | 41.69 Mn |
| Mar 31, 2025 | 41.69 Mn |
| Dec 31, 2024 | -2.21 Mn |
| Dec 31, 2024 | -2.21 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 80.83 Mn |
| Mar 31, 2024 | 80.83 Mn |
| Dec 31, 2023 | -725,000.00 |
| Dec 31, 2023 | -725,000.00 |
| Sep 30, 2023 | 380,000.00 |
| Sep 30, 2023 | 380,000.00 |